Skip to content

Ispire Technology Inc. ISPR Issuance of warrants to purchase common stock

Issuance of warrants to purchase common stock at other companies

Ispire Technology Inc. logo
Ispire Technology Inc.ISPR
$91.49K
Envoy Medical logo
Envoy MedicalCOCH
$882K+348%
CO2 Energy Transition Corp. Common Stock logo
CO2 Energy Transition Corp. Common StockNOEM
$51.75K
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$2.52M-75.7%
ADMA Biologics logo
ADMA BiologicsADMA
$1.4M
Evommune
 logo
Evommune EVMN
$150

Other financials

Income statement

See full
Revenue$18.7M-28.7%
Gross profit$2.0M-58.3%
Operating income-$9.5M+10.4%
Net income-$9.5M+12.3%
EPS (diluted)-$0.17+10.5%

Balance sheet

See full
Cash & equivalents$18.0M-23.6%
Total debt$3.8M-40.8%
Total equity-$16.2M-210%
Total assets$75.9M-34.4%

Cash flow

See full
Operating cash flow-$4.0M
CapEx$247.3K
Free cash flow-$4.0M

Valuation

See full
Market cap$64.29M-46.9%
Enterprise value$50.07M-51.3%
P/S0.7×-0.2×

Profitability

See full
Gross margin14.6%-6.6pp
Operating margin-37.7%-871pp
Net margin-38.2%+1,627pp
FCF margin-27.4%-31.5pp

Returns & leverage

See full
Return on equity-223.8%-299pp
Debt / equity9.8×+9.7×
Current ratio0.0×

Where this comes from

Reported directly by Ispire Technology Inc. in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued.

The official record: Ispire Technology Inc.’s 10-K, filed September 15, 2025, on SEC EDGAR. View the filing →

Ask your AI about Ispire Technology Inc.'s issuance of warrants to purchase common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ispire Technology Inc.'s issuance of warrants to purchase common stock?
Ispire Technology Inc. (ISPR) reported issuance of warrants to purchase common stock of $91.49K in Q2 2024.
What does issuance of warrants to purchase common stock mean?
Measures the value assigned to warrants issued to purchase common stock, typically granted as part of financing arrangements or strategic partnerships. This metric indicates the potential future dilution and the cost of capital associated with these derivative instruments. It helps investors assess the long-term impact on equity structure.